QIAGEN and ICMP launch next-generation DNA testing solutions for identifying missing persons
The Hague, 24 October 2017 – The International Commission on Missing Persons (ICMP) today announced the launch of a cutting-edge next-generation sequencing (NGS) workflow created in collaboration with QIAGEN N.V. for ICMP's missing persons DNA identification laboratory in The Hague. The solution integrates QIAGEN’s GeneReader NGS System and spans all aspects of the DNA laboratory workflow, from sample extraction through final analysis and thereby creates a unique “sample to insight” user experience. The workflow includes automated QIAGEN instruments and consumables for DNA extraction, liquid handling, quantification, sample preparation and next generation, Massively Parallel Sequencing (MPS).
“QIAGEN’s support for ICMP is timely, focused, and substantial,” ICMP Director-General Kathryne Bomberger said today. “Our partnership with QIAGEN and other leading technology companies makes it possible for us to maintain the ICMP laboratory system as the premier high-throughput, human identification DNA laboratory system in the world that is capable of responding – quickly, economically and effectively – to missing persons scenarios wherever they arise.”
QIAGEN Chief Executive Officer Peer Schatz said, “This collaboration springs from a shared passion for applying state-of-the-art technologies to address a very important and very challenging need. Wars, disasters and other events that separate victims from families leave behind unanswered questions and tremendous grief. We believe that that application of these state of the art technologies to this need has the potential to provide help to those experiencing such terrible uncertainty. ICMP’s global role in securing the cooperation of governments and other agencies to account for complicated or large-scale missing persons scenarios requires the very best DNA analysis workflow, and achieving this is a further example of QIAGEN’s mission of making improvements in life possible.”
ICMP and a number of academic institutes have worked closely with QIAGEN to develop a powerful SNP (single nucleotide polymorphism) panel specifically designed for missing persons identification. The ICMP MPs-Plex targets more than 1,400 sites in the human genome, capitalizing on the power provided by Massively Parallel Sequencing. In addition to the custom panel, QIAGEN will supply software, reagents, consumables and technical support on an ongoing basis for ICMP.
Since 2001, ICMP has operated a state-of-the-art DNA laboratory system focused exclusively on missing persons identification. The system delivers high-throughput capabilities to assist governments in identifying large numbers of persons missing from conflict, human rights abuses, natural and manmade disasters, organized crime, irregular migration and other circumstances where persons go missing for involuntary reasons.
The system is designed to work on the most challenging cases, operates on a high-throughput scale, has generated DNA results on more than 50,000 cases of degraded skeletal remains and contributed to the identification of around 20,000 persons worldwide. ICMP’s new laboratory in The Hague aspires to maintain a capacity of up to 10,000 cases a year. Over the course of two decades, ICMP has responded to a wide variety of complex missing persons scenarios in over 40 countries, including assisting Bosnia and Herzegovina identify almost 90 percent of the approximately 8,000 victims of the Srebrenica genocide, and after the 2004 South East Asian Tsunami, in conjunction with INTERPOL, it deployed its forensic expertise as part of a major international Disaster Victim Identification program. The laboratory system is also a key component of ICMP’s Center of Excellence in Training and it supports ICMP's programs in the Western Balkans, the MENA region and Latin America.
ICMP is a treaty-based international organization based in The Hague, the Netherlands. Its mandate is to secure the cooperation of governments and others in locating and identifying missing persons from conflict, human rights abuses, disasters, organized crime, irregular migration and other causes and to assist them in doing so. It is the only international organization tasked exclusively to work on the issue of missing persons.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA), a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2017, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.QIAGEN.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted EPS, adjusted gross profit, adjusted operating income, adjusted net income attributable to owners of QIAGEN N.V. and free cash flow results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).